Metabolic engineering of Escherichia coli for efficient production of L-5-hydroxytryptophan from glucose.
Study Design
- Tipo di studio
- laboratory / metabolic engineering study
- Intervento
- Metabolic engineering of Escherichia coli for efficient production of L-5-hydroxytryptophan from glucose. not applicable
- Comparatore
- Placebo
- Direzione dell'effetto
- Positive
- Rischio di bias
- Low
Abstract
BACKGROUND: 5-hydroxytryptophan (5-HTP), the direct biosynthetic precursor of the neurotransmitter 5-hydroxytryptamine, has been shown to have unique efficacy in the treatment of a variety of disorders, including depression, insomnia, and chronic headaches, and is one of the most commercially valuable amino acid derivatives. However, microbial fermentation for 5-HTP production continues to face many challenges, including low titer/yield and the presence of the intermediate L-tryptophan (L-Trp), owing to the complexity and low activity of heterologous expression in prokaryotes. Therefore, there is a need to construct an efficient microbial cell factory for 5-HTP production. RESULTS: We describe the systematic modular engineering of wild-type Escherichia coli for the efficient fermentation of 5-HTP from glucose. First, a xylose-induced T7 RNA polymerase-PT7 promoter system was constructed to ensure the efficient expression of each key heterologous pathway in E. coli. Next, a new tryptophan hydroxylase mutant was used to construct an efficient tryptophan hydroxylation module, and the cofactor tetrahydrobiopterin synthesis and regeneration pathway was expressed in combination. The L-Trp synthesis module was constructed by modifying the key metabolic nodes of tryptophan biosynthesis, and the heterologous synthesis of 5-HTP was achieved. Finally, the NAD(P)H regeneration module was constructed by the moderate expression of the heterologous GDHesi pathway, which successfully reduced the surplus of the intermediate L-Trp. The final engineered strain HTP11 was able to produce 8.58 g/L 5-HTP in a 5-L bioreactor with a yield of 0.095 g/g glucose and a maximum real-time productivity of 0.48 g/L/h, the highest values reported by microbial fermentation. CONCLUSION: In this study, we demonstrate the successful design of a cell factory for high-level 5-HTP production, combined with simple processes that have potential for use in industrial applications in the future. Thus, this study provides a reference for the production of high-value amino acid derivatives using a systematic modular engineering strategy and a basis for an efficient engineered strain development of 5-HTP high-value derivatives.
Full Text
Figures
Fig. 1
Biosynthetic pathway diagram for L-5-hydroxytryptophan production from glucose in engineered Escherichia coli. Key enzymatic steps including tryptophan hydroxylase and cofactor regeneration pathways are highlighted as targets for metabolic engineering.
diagram
Fig. 2
Comparison of 5-HTP titers from different E. coli strain variants engineered with various combinations of pathway modifications. Iterative optimization of the biosynthetic route yielded progressively higher 5-HTP accumulation from glucose.
chart
Fig. 3
Fed-batch fermentation profiles showing 5-HTP production, glucose consumption, and cell growth over time in the optimized E. coli strain. Production kinetics demonstrate the scalability of the engineered pathway for industrial 5-HTP biosynthesis.
chart
Fig. 4
Analysis of L-tryptophan intermediate accumulation and its relationship to 5-HTP yield in engineered E. coli strains. Minimizing tryptophan overflow is a critical factor in maximizing conversion efficiency to 5-HTP.
chart
Fig. 5
Cofactor balance analysis showing tetrahydrobiopterin (BH4) or related cofactor levels in the 5-HTP-producing E. coli strains. Adequate cofactor supply is essential for tryptophan hydroxylase activity and efficient 5-HTP biosynthesis.
chart
Fig. 6
Summary of metabolic flux distribution in the optimized E. coli strain producing 5-HTP from glucose. The engineered pathway channels carbon flux through the shikimate and tryptophan branches toward efficient hydroxytryptophan formation.
diagramTables
Table 1
| Promoters | Sequence a | Strength b |
|---|---|---|
| lacZ |
| 0.3 |
| M1–12 | TTATCTCTGGCGGTG | 0.1 ± 0.01 |
| M1–30 | TTATCTCTGGCGGTG | 0.7 ± 0.04 |
| M1–46 | TTATCTCTGGCGGTG | 1.5 ± 0.1 |
| M1–37 | TTATCTCTGGCGGTG | 1.9 ± 0.12 |
| M1–93 | TTATCTCTGGCGGTG | 4.0 ± 0.12 |
Table 2
| Host | Hydroxylases | Cofactors | Cultivation mode | medium type | Titer (g/L) | Reference |
|---|---|---|---|---|---|---|
|
| Phenylalanine 4-hydroxylase form | BH4 | Shake flask; Supplementation of 5 mM L-Trp | - | 0.55 | Hara et al., 2013 [ |
|
| Phenylalanine-4-hydroxylase from | MH4 | Shake flask; Supplementation of 2 g/L L-Trp | M9 minimal medium | 1.1–1.2 | Lin et al.,. 2014 [ |
|
| Aromatic amino acid hydroxylase from | BH4 | Supplementation of 1 g/L L-Trp | Mineral medium | 0.55 | Mora-Villalobos et al., 2017 [ |
|
| Aromatic amino acid hydroxylase from | MH4 | Fed-batch | Mineral medium | 0.962 | Mora-Villalobos et al., 2018 [ |
|
| Human TPH2 mutant with a deletion of first 145 N-terminal and 24 C-terminal aminoacids (TPH2, NΔ145/CΔ24) | BH4 | Fed-batch; Glycerol as carbon source | Mineral medium | 5.1 | Wang et al., 2018 [ |
|
| Truncated human TPH2 (NΔ145/CΔ24) | BH4 | Shake flask; Glycerol as carbon source | Mineral medium | 1.61 | Xu et al., 2020 [ |
|
| Truncated human TPH2 (NΔ145/CΔ24) with mutations of E2K, N97I and P99C | BH4 | Fed-batch; Glucose as carbon source | Mineral medium | 8.58 | This study |
Table 3
| Strains | Characteristics | Source |
|---|---|---|
|
| Host for cloning | Lab stock |
|
| Wild type, starting strain | Lab stock |
| HTP01 |
| This study |
| HTP02 | HTP01, | This study |
| HTP03 | HTP02, | This study |
| HTP04 | HTP03, pSTV-TM | This study |
| HTP05 | HTP03, pSTV-TM1 | This study |
| HTP06 | HTP03, pSTV-TM2 | This study |
| HTP07 | HTP06, | This study |
| HTP08 | HTP07, | This study |
| HTP09 | HTP08, | This study |
| HTP10 | HTP09, | This study |
| HTP11 | HTP09, | This study |
| HTP12 | HTP09, | This study |
| HTP13 | HTP09, | This study |
| HTP14 | HTP09, | This study |
| Plasmid | ||
| pGRB | gRNA expression vector | Lab stock [ |
| pRed-cas9 | Cas9 expression vector | Lab stock [ |
| pSTV28 | P15A ori, CmR, | Lab stock |
| pSTV-TM | pSTV28, P | This study |
| pSTV-TM1 | pSTV28, P | This study |
| pSTV-TM2 | pSTV28, P | This study |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Sleep medicine reviews · 2011
A systematic review of insomnia and complementary medicine.
Alternative medicine review : a journal of clinical therapeutic · 1998
5-Hydroxytryptophan: a clinically-effective serotonin precursor.
Annual review of nutrition · 2021
Sleep and Diet: Mounting Evidence of a Cyclical Relationship.
Psychosomatic medicine · 1999
Dietary supplements and natural products as psychotherapeutic agents.
Drugs & aging · 2018